Wall Street closes at a record for the first time since end of January
Lyra Therapeutics, Inc. (NASDAQ:LYRA) has entered into agreements to terminate its leases for two Massachusetts facilities ahead of schedule, according to a statement filed with the Securities and Exchange Commission. The lease terminations come as the company faces mounting financial pressures, with a market capitalization of just $940,000 and a stock price that has plunged 87.5% over the past year to $0.53. InvestingPro data reveals the company is quickly burning through cash with negative free cash flow of $29 million, while 15 additional ProTips highlight critical financial challenges facing the biotech firm.
On March 31, Lyra Therapeutics signed an agreement with ARE-480 Arsenal Street, LLC to end its lease for approximately 22,343 square feet at 480 Arsenal Way, Watertown. The lease, originally set to expire on April 30, 2027, will now end no later than May 31, 2026. As part of the agreement, Lyra Therapeutics will forfeit a $302,514.84 letter of credit security deposit and pay a lease modification fee of $1,000,000. If the company completes a defined sale transaction, it will also pay 10% of the net cash proceeds from the transaction, up to $1,500,000. The company’s rent obligations for this property ended on January 31.
On April 7, the company entered into a separate agreement with BXP Waltham Woods LLC to terminate its lease for approximately 28,858 square feet at 880 Winter Street, Waltham. This lease was originally scheduled to expire on June 30, 2033, and will now end on May 31, 2026. Lyra Therapeutics will forfeit a $1,089,389 letter of credit security deposit and pay a termination fee of $1,500,000. These payments are considered liquidated damages. Rent obligations for the Waltham property ended on March 31. The agreement includes mutual releases between the company and the landlord effective as of the termination date.
The information is based on a press release statement filed with the SEC.
In other recent news, Lyra Therapeutics has received a notice of default from RVAC Medicines regarding unpaid rent for its office space in Waltham, Massachusetts. The notice, dated February 23, follows the company’s previous announcement to cease operations and pursue a wind-down. The total unpaid rent amounts to $484,431.92, as detailed in an SEC filing. Additionally, Lyra Therapeutics has announced the suspension of further development of LYR-210, its lead product candidate for chronic rhinosinusitis. This decision has led to a workforce reduction impacting all 28 remaining employees. The company is working with SSG Capital Advisors to explore strategic alternatives. Both CEO Maria Palasis and CFO Jason Cavalier will remain involved as consultants during this process. These developments indicate significant changes for Lyra Therapeutics as it navigates its current challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.